drugset / Trial / NCT02301494
Effectiveness of Imiquimod Topical Cream in Early Stage Cutaneous T-cell Lymphoma
Withdrawn
Rochester General Hospital
Bausch Health Americas, Inc. · collabRochester Skin Lymphoma Medical Group, PLLC · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is being conducted by Brian Poligone, MD PhD. The purpose of this study is to determine safety, effectiveness, and tolerability of two topical therapies, imiquimod and fluocinonide, for patients with early stage Cutaneous T-cell Lymphoma (CTCL).
Timeline
- Start
- 2020-04
- Primary completion
- 2022-04
- Completion
- 2023-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fluocinonide | Other / unclassified | 0.1 % | Topical |
| Subject | Imiquimod | Other / unclassified | 3.75 % | Topical |